SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-169953
Filing Date
2021-05-24
Accepted
2021-05-24 07:09:32
Documents
14
Period of Report
2021-05-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d58583d8k.htm   iXBRL 8-K 26967
2 EX-99.1 d58583dex991.htm EX-99.1 42232
6 GRAPHIC g58583g60d75.jpg GRAPHIC 6319
  Complete submission text file 0001193125-21-169953.txt   211609

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ngm-20210524.xsd EX-101.SCH 3060
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20210524_lab.xml EX-101.LAB 18122
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20210524_pre.xml EX-101.PRE 11399
7 EXTRACTED XBRL INSTANCE DOCUMENT d58583d8k_htm.xml XML 3419
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 21951060
SIC: 2834 Pharmaceutical Preparations